Market Landscaping for Launch Planning Get more launch planning insights Consulting > Market Landscaping for Launch Planning Localizing your global pipeline for Nordic success The journey from EMA approval to payer acceptance is filled with hurdles. You must secure a recommendation from HTA bodies such as the Danish Medicines Council, identify the right stakeholders, understand local treatment patterns, and demonstrate your product’s value to local HCPs. We help you adapt your global launch strategy to fit the Nordic reality, removing complexity and saving you valuable time and resources. Get a launch plan workshop 360° launch acceleration framework Launching a new medicinal product or extending indications of existing therapies requires coordination across multiple teams and local market expertise.Our team of experts in stakeholder insights, market access and RWE supports your journey from approval to payer acceptance and patient treatment. This diverse expertise ensures your launch process will be covered from a 360° perspective. Treatment environment assessment We provide a comprehensive overview of the existing clinical practice and framework your product will enter Barriers and opportunities We help you uncover the challenges and potential advantages for your product launch across Nordic healthcare systems Real-world evidence follow-up We track patient journeys and treatment patterns using sales data and our authorized access to Danish and Nordic health registries Indication expansion Expanding your product’s approved indications represents a significant opportunity to increase market reach and extend the product lifecycle. Our support for indication expansions includes: Analysis of real-world usage patterns to identify potential new indications Evidence generation to support regulatory submissions for additional indications Assessment of market opportunity and competitive landscape for new indications Health economic modeling to demonstrate value in additional patient populations Stakeholder mapping for the new indication’s treatment pathway Your indication expansions become a clear path to broader impact, with expert guidance from evidence generation to HTA-board recommendation. Market research as your compass for Nordic success What are local HCPs’ pain points with current treatments? What unmet needs exist? What is the market maturity and readiness for your product? Our market research answers these crucial questions, transforming your global launch package into a Nordic success story. Through customized research designs, we uncover rational and emotional drivers influencing key stakeholders. This pre-launch research should begin one to two years before launch when you receive the global launch package from headquarters. If you think that’s plenty of time; it isn’t. Those 12-24 months can determine whether your product reaches patients or gets stuck in regulatory limbo. For affiliates in the Nordics managing multiple annual launches, our tactical approach reduces administrative burden, helping your products reach patients faster. When your product requires changes in diagnosis testing, handling, or patient monitoring, our research helps bridge the gap between current clinical practice and the ideal future clinic. This process worked effectively in our melanoma immunotherapy research, where we uncovered crucial factors influencing treatment decisions. Similarly, our work on hereditary heart conditions identified significant opportunities in a field with minimal recent innovation. Break through the market access barrier Positioning your product effectively and highlighting its unique selling points is essential when competing in a crowded market. We understand that many product launches fail to reach even half of their forecasts – outcomes that could be dramatically improved with proper market knowledge, advisory, and data analytics. Our approach integrates market access planning early in your product journey, ideally starting prior to Phase II clinical trials, ensuring that commercial considerations shape your development strategy. However, we provide support at any stage of your product lifecycle, whether you’re in early development or preparing for an imminent launch. Success with the Danish Medicines Council or another Nordic HTA board depends on deep local expertise and compelling evidence of your product’s value. We help you: Develop robust health economic models Create persuasive value narratives Prepare thorough submission applications that address clinical and financial considerations The role of Real-World Evidence Real-world evidence (RWE) plays a crucial role in your product life cycle by providing insights that clinical trials alone cannot deliver: RWE reveals treatment patterns and adherence, indicating potential barriers for uptake RWE documents patient outcomes, strengthening your case for Health Technology Assessment applications and reimbursement applications We help identify regions and hospitals most likely to adopt your product quickly Our analyses help you understand your total addressable market with precision We can evaluate the effectiveness and safety of your drug post-launch By leveraging our exclusive access to healthcare registries across the Nordic countries, we provide evidence-based insights that support your strategy and help you demonstrate your product’s value in real-world settings. Map out your key opinion leaders who amplify your success Which HCPs connect patients to new treatments in your field? When launching a product, identifying these clinical influencers who champion innovative approaches is essential. Your field force needs to engage with these key voices, who might not be the most published specialists. Our Key Opinion Leader solution maps professional networks within your specific disease or treatment area, identifying important healthcare professionals who can support your market access and Health Technology Assessment processes. The analysis provides concrete data on each professional’s market influence, research connections, and publication history. With this knowledge, you can prioritize your outreach efforts and build relationships with the healthcare professionals who will drive your product’s adoption. Understand your patient for effective adoption Success in the crucial early months after launch depends on knowing exactly who your patients are and where to find them. Our two specialized data solutions give you this vital intelligence when you need it most. Patient Impact Planner analyzes anonymized patient data to reveal aggregate treatment patterns, geographic distribution, and prescription fulfillment locations. This helps you target pharmacy campaigns and field force efforts precisely during your launch phase. Indication Insights tracks market share development by indication, allowing you to monitor your launch progress with specific patient groups. By combining sales data with National Patient Register information, we show you where the highest concentration of relevant patients can be found and adjust your launch strategy accordingly. For more information, please contact Jonas Arentz Bach Nordic Sales Director jab@signumlifescience.com +45 40 417 546 Frequently asked questions Click on the arrow to expand How does market landscaping help global pharma teams adapt their launch strategy to Nordic healthcare realities? Market landscaping identifies local treatment patterns, stakeholder expectations, HTA requirements, and real-world barriers that global launch packages often overlook. By tailoring strategy to Nordic practices, companies avoid misalignment, reduce delays, and increase the likelihood of payer acceptance and clinical adoption. How can early-stage market landscaping influence success with HTA bodies like the Danish Medicines Council? Starting landscape assessments before Phase II ensures your clinical strategy incorporates Nordic evidence expectations. Early integration of local value drivers leads to stronger submissions, more persuasive value narratives, and a clearer justification for reimbursement and for inclusion in treatment guidelines. How does a 360° launch acceleration framework support a successful pharmaceutical launch in the Nordics? A 360° launch acceleration framework guides your product from early development to post-launch growth. It maps the treatment environment, identifies local barriers and opportunities, and uses real-world evidence to track patient journeys and adoption. This coordinated approach helps you align with Nordic clinical practice, anticipate challenges, and prepare for a smoother, more successful launch. How does pre-launch market research shape a more successful Nordic launch? Pre-launch research identifies unmet needs, HCP pain points, emotional and rational drivers, readiness factors, and gaps in current clinical practice. Beginning this research 12–24 months before launch allows time to influence strategy, refine messaging, and build a launch plan that resonates with local stakeholders. How can market landscaping help identify the stakeholders who matter most for launch success? Using stakeholder mapping and key opinion leader network analysis, market landscaping pinpoints the HCPs who guide treatment decisions, shape clinical behavior, and impact payer evaluations. This ensures field force efforts and scientific engagement focus on the voices that truly drive adoption. Why is launch planning particularly demanding for Nordic affiliates managing multiple launches each year? Nordic affiliates often oversee several launches in parallel, each with its own regulatory path, HTA expectations, and clinical considerations. Market landscaping reduces administrative burden by delivering a clear, structured, and prioritized roadmap for each product’s launch trajectory.
